

Title (en)

Oral recombinant lactobacilli vaccines

Title (de)

Oraler Impfstoff enthaltend rekombinanten Lactobacilli

Title (fr)

Vaccin oral contenant des Lactobacilli recombinés

Publication

**EP 1084709 A9 20010516 (EN)**

Application

**EP 99203056 A 19990917**

Priority

EP 99203056 A 19990917

Abstract (en)

[origin: EP1084709A1] The present invention relates to an oral vaccine comprising recombinant lactic acid bacteria expressing heterologous antigen in vivo intracellularly and/or the surface of the lactic acid bacterium as specific immunogenicity eliciting component for eliciting immunogenicity against the heterologous antigen, characterised in that the recombinant lactic acid bacterium is a Lactobacillus plantarum. Preferably, the recombinant Lactobacillus plantarum comprises an expression vector capable of expressing the heterologous antigen intracellularly and/or such that the heterologous antigen is exposed on the cell surface under conditions present in the gastrointestinal tract. The recombinant Lactobacillus plantarum is preferably a recombinant Lactobacillus plantarum 256. The invention also relates to a recombinant Lactobacillus plantarum, more specifically a recombinant strain of Lactobacillus plantarum 256, for use in the vaccines of the invention; as well as to an expression vector suitable for intracellular expression or exposure of a heterologous antigen encoded thereon, said expression vector providing expression in a Lactobacillus plantarum of the heterologous antigen under conditions existing in the gastrointestinal tract.

IPC 1-7

**A61K 39/00**; **C12N 15/74**

IPC 8 full level

**C12N 15/09** (2006.01); **A61K 35/74** (2015.01); **A61K 35/747** (2015.01); **A61K 39/00** (2006.01); **A61K 48/00** (2006.01); **A61P 31/04** (2006.01); **A61P 31/10** (2006.01); **A61P 31/12** (2006.01); **A61P 33/02** (2006.01); **A61P 37/08** (2006.01); **C12N 1/21** (2006.01); **C12N 15/74** (2006.01); **C12R 1/25** (2006.01)

CPC (source: EP US)

**A61K 35/747** (2013.01 - EP); **A61K 39/00** (2013.01 - EP US); **A61P 31/04** (2018.01 - EP); **A61P 31/10** (2018.01 - EP); **A61P 31/12** (2018.01 - EP); **A61P 33/02** (2018.01 - EP); **A61P 37/08** (2018.01 - EP); **C12N 15/746** (2013.01 - EP); **A61K 2039/523** (2013.01 - EP); **A61K 2039/542** (2013.01 - EP); **Y02A 50/30** (2018.01 - EP)

Cited by

EP1723965A1; US8821893B2; US8691214B2; KR20160037879A; EP3009149A4; US10314916B2; WO2006123230A3; WO2014047625A1; WO2005040387A1; WO2007106073A3; US8802419B2; US9138468B2; US9452205B2; US9931390B2; WO03063785A3; EP1523559A1

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

**EP 1084709 A1 20010321**; **EP 1084709 A9 20010516**; AP 2002002445 A0 20020331; AU 7433700 A 20010424; CA 2383433 A1 20010329; CN 1387442 A 20021225; EP 1212083 A1 20020612; IL 148713 A0 20020912; JP 2003509469 A 20030311; OA 12023 A 20060419; WO 0121200 A1 20010329; ZA 200201969 B 20030827

DOCDB simple family (application)

**EP 99203056 A 19990917**; AP 2002002445 A 20000918; AU 7433700 A 20000918; CA 2383433 A 20000918; CN 00815334 A 20000918; EP 00962689 A 20000918; GB 0003575 W 20000918; IL 14871300 A 20000918; JP 2001524624 A 20000918; OA 1200200076 A 20000918; ZA 200201969 A 20020308